


SUPPLEMENTARY MATERIAL

SUPPLEMENTARY FIGURE 1 Study design



PsO, psoriasis.

SUPPLEMENTARY TABLE 1 Systemic treatments of interest

Drug class	Drug generic name	Treatment interval, days (Upon maintenance dosing schedule)
TNF inhibitor	Infliximab, including biosimilars	56
	Adalimumab, including biosimilars	14
	Certolizumab pegol	14
IL-12/23 inhibitor	Ustekinumab	84
IL-17 inhibitor	Secukinumab	28
	Ixekizumab	28
	Brodalumab	14
IL-23 inhibitor	Guselkumab	56
	Risankizumab	84
	Tildrakizumab	84
PDE-4 inhibitor	Apremilast	NA
Immunosuppressants	Cyclosporin	NA
	Methotrexate	NA
Vitamin A	Etretinate	NA

IL, interleukin; NA, not applicable; PDE-4, phosphodiesterase-4; TNF, tumor necrosis factor.